Announcements Trials

Browse Landscape

Status

Active not recruiting 2 Terminated 1 Recruiting 1 Completed 1 Available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

balstilimab 2 3-Iodobenzylguanidine 2 zolbetuximab 1 zipalertinib 1 venetoclax 1 ulixertinib 1 tisagenlecleucel 1 talazoparib 1 selinexor 1 ruxolitinib 1 ribociclib 1 nirogacestat 1 mirdametinib 1 mifamurtide 1 lifileucel 1 leronlimab 1 idecabtagene vicleucel 1 fluorodopa F 18 1 fluorocholine 1 dodecyl maltoside 1 carbon-11 methionine 1 brexucabtagene autoleucel 1 axicabtagene ciloleucel 1 asciminib 1 Sunitinib 1 Proton Pump Inhibitors 1 Peripheral Blood Stem Cell Transplantation 1 Methionine 1 Magnetic Resonance Spectroscopy 1 LY3023414 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Available × LY3023414 × 1 year × Clear all

NCT02632994 2025-09-29

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Eli Lilly and Company

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡